Editorial
Pacific trial: a new ocean or an abnormal wave?
Abstract
Recently, Antonia et al. (1) have published a phase III randomized trial exploring durvalumab after concurrent chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC).
